Marengo Therapeutics is pioneering a new way to activate the body’s own immune system to treat disease. The mission of Marengo is to activate the right immune cells to promote lifelong protection against cancer. Using their understanding of T-cell receptor (TCR) biology, Marengo is designing therapies to activate a subset of T-cells known as tumor-infiltrating lymphocytes. With their versalite antibody technology platform, Marengo can modulate this subset of T-cells in different ways to support the rapid development of clinic-ready therapeutics for various diseases. Marengo’s lead candidate, START-001, is already in clinical trials for advanced antigen-rich solid tumors.

Marengo Therapeutics

AACR 2025 Tracker: Merck, GSK, Roche and More Present Key Data - BioSpace

Ipsen and Marengo Therapeutics announce second strategic - GlobeNewswire

 Ipsen nominates drug candidate from Marengo partnership 

 Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen 

Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe - PR Newswire

Ipsen and Marengo Expand Oncology Partnership with Next-Generation T Cell Engager Technology - The Healthcare Technology Report.

 Ipsen returns to Marengo Therapeutics for new trispecific deal 

Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic - PR Newswire

Marengo Launches to Uniquely Activate T Cells Against Cancer - BioSpace

Marengo to Share Updated Clinical Results from STARt-001 Phase 1/2 Clinical Trial Featuring Invikafusp Alfa Monotherapy Activity in PD1 Resistant Tumors at Upcoming AACR 2025 Clinical Plenary Oral Presentation - PR Newswire

 STAT+: Up and down the ladder: The latest comings and goings 

Are you attending ESMO IO?  Don't miss Marengo CEO Zhen Su, MD MBA presenting Phase I clinical data on Friday, December 13, 10:30-12 noon CET.

Last week, some of our team had the opportunity to attend the Massachusetts Conference for Women, and we couldn’t be more inspired by the impactful conversations, empowering sessions, and invaluable connections made throughout the event. Hearing from accomplished women driving innovation and excellence in their industries left us feeling motivated and ready to bring new ideas and energy to our work. The conference was a powerful reminder of the importance of collaboration and continuous learning in achieving success. A huge thank you to the organizers, speakers, and everyone who made this event a success. It was an amazing opportunity to engage with inspiring professionals, exchange ideas, and gain valuable insights to advance our efforts.

We’re excited to take these lessons and put them into action as we continue to drive progress within our team and the biotech industry.
#WomenInBusiness #Inspiration #Teamwork #Innovation #Biotech

 Marengo Announces First Patient Dosed in Phase 2 Clinical Study for its Lead Program, Invikafusp Alfa (STAR0602) in PD-1 Resistant Tumors, Expands Study to Europe 

 Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 



			
				03/28/2025
				In the news
			

			
				Precision Medicine Online: Marengo Therapeutics Looks to Mimic ‘Natural’ Immune Response…
			

			
				Read More
			

		

Marengo Appoints Dr. Everett Vokes To Scientific Advisory Board - citybiz

Ipsen extends Marengo partnership with $1.2bn T cell research deal - Pharmaceutical Technology

Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen - PR Newswire

 Marengo's TriSTAR technology attracts second Ipsen deal for $1.2B 

 Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer 

Today James Gulley MD PhD FACP presented our Late Breaking Oral First in Human clinical data from our lead program invikafusp alfa (STAR0602) as monotherapy in PD1 resistant cancers at Society for Immunotherapy of Cancer (SITC).

To learn more details of the presentation and results read our press release:
https://lnkd.in/egvHspHu

 Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting 

Marengo's First-in-Class Invikafusp Alfa (STAR0602) Receives U.S. FDA Fast Track Designation for Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancers with High Tumor Mutational Burden (TMB-H) - PR Newswire

Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting - PR Newswire

 Marengo Therapeutics Appoints Elena Garralda to its Scientific Advisory Board 

A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity - Science

March brought some incredible new talent through our doors, however we’ve been so busy onboarding our amazing new teammates that we didn’t have time to post about them (oops)… until now! 
Please join us in giving an official Marengo welcome to our new March colleagues: 🎉 Ryan Goodwin and Srikanth Kurra. Welcome to the team!

#NewHires #WelcomeToTheTeam #BetterLateThanNever #MarengoTherapeutics

 Combination therapies using molecules binding to tcr 

Ipsen jumps into the TCR space, teaming with startup helmed by former Merck KGaA cancer chief - Endpoints News

Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine - PR Newswire

 Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from ... 

ATP fuels Marengo with $80M for battle against cancers with former Merck KGaA oncology head in driver's seat - Fierce Biotech

 Ipsen and Marengo Therapeutics announce strategic partnership 

Marengo is excited to disclose updated results from our STARt-001 Phase 1/2 trial evaluating invikafusp alfa (STAR0602) in anti-PD(L)1-resistant, antigen-rich tumors—selected for plenary oral presentation at #AACR25.

We believe this represents the first clinical validation of a precision T cell agonist approach for patients who have exhausted checkpoint inhibitors. Don't miss additional new clinical data shared during our plenary oral presentation on Tuesday April 29 in Chicago.

Read the full announcement: https://lnkd.in/ey8h_rji

#immunotherapy #oncology #Tcellactivation #biotech #MarengoTherapeutics #AACR2025

 Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference 

Marengo's STAR shines as Ipsen hands over $45M for 2 preclinical T-cell activators - Fierce Biotech

We are proud to share that Marengo will be presenting during the Clinical Plenary Oral Session at the upcoming American Association for Cancer Research (AACR) Annual Meeting!

We look forward to sharing updated clinical results from our STARt-001 trial studying Invikafusp alfa as a monotherapy in PD1 resistant tumors.

👉 Read the full press release here: https://lnkd.in/dGrgRzPT

 Stay tuned for more details — we hope to see you in Chicago next month!

#AACR25 #CancerResearch #OncologyInnovation #MarengoTherapeutics #ImmunoOncology

Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers - PR Newswire

Ipsen makes TCR play, grabbing two I-O therapies from Marengo - pharmaphorum

Marengo to Share Updated Clinical Data of Invikafusp Monotherapy Activity in PD1 resistant tumors in a Clinical Plenary Oral Presentation at AACR 2025 - PR Newswire

 Multifunctional molecules binding to tcr and uses thereof 

Marengo’s TriSTAR technology attracts second Ipsen deal for $1.2B - BioWorld Online

 Epstein Barr Virus Treatment Market 2034: FDA Approvals, Clinical Trials, Drugs, Medication, Companies by DelveInsight 

Marengo closes $80M A round to harness novel antibody-mediated T-cell activation for cancer - BioWorld MedTech

Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board - PR Newswire

 Ipsen to Pay Marengo Therapeutics Up to $1.2B Under Expanded Cancer Research Partnership 

 Tcr targeting molecules and uses thereof 

 Anti-tcr antibody molecules and uses thereof 

 Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers 

Apple Tree Partners breaks into UK with biotech Adendra Therapeutics launch, $53M series A raise - Fierce Biotech

Firm Advises Marengo Therapeutics on Expansion of Research Partnership with Ipsen - Wilson Sonsini

Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation - PR Newswire

Join Marengo Therapeutics CEO Zhen Su, MD MBA at the upcoming Longwood Healthcare Leaders Boston CEO event on October 28 - 29, 2024! Zhen will be speaking at the event, taking part in a panel with other industry leaders on the topic of expanding platform potential.

More information: https://lnkd.in/eehfZ2xB

#longwoodhealthcareleaders #ceo #biotech

ATP fuels Marengo with $80M for battle against cancers ...

Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting - PR Newswire

At Marengo Therapeutics we’re passionate about science and service, and getting our hands dirty (literally) reminds us just how connected innovation and impact can be!
For our first volunteer event of 2025 we spent the morning with The Food Project, a non-profit organization that focuses on community improvement and outreach, and education about health, leadership and sustainable agriculture. We spent the morning planting seedlings, preparing beds and greenhouses, and cleaning growing trays ahead of harvest later this year.

Huge thanks to The Food Project for letting us be part of something so “rooted” in purpose! 
We left with tired muscles, full hearts, and a whole new appreciation for where our food comes from. To learn more about The Food Project check out their website: https://lnkd.in/eTqHb4g 
#BiotechForGood #CommunityImpact #VolunteerDay #ScienceMeetsSoil


                Four from Penn elected to the National Academy of Sciences | Penn Today
              

We're "picking" the best talent this October: Joining the Marengo team this week is Cathy Chen and Larkin De Laria - They're the pick of the (pumpkin) patch!
 
Check out our current open roles: https://lnkd.in/eQCzHw7z

Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer - PR Newswire

Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute - PR Newswire

Invikafusp Alfa Earns FDA Fast Track Designation in Locally Advanced CRC - Cancer Network

This morning, Marengo Therapeutics announced that our first patient was dosed in our Phase 2 study of STAR0602, and that we have expanded the clinical study to premium oncology centers across Europe. 

Read our press release here: https://lnkd.in/gcMDAkwR
Ke Liu , MD, PhD   Zhen Su, MD MBA Kevin Chin Andrew Bayliffe ATP (Apple Tree Partners)



			
				04/30/2025
				In the news
			

			
				Biospace: AACR 2025 Tracker: Marengo, BriaCell, Present Promising Data
			

			
				Read More
			

		

Marengo to Present Clinical Data Highlighting Invikafusp Alfa (STAR0602), a First-in-Class Selective, Dual T Cell Agonist at ESMO Immuno-Oncology Congress 2024 - PR Newswire

 Marengo Appoints Dr. Everett Vokes to the Scientific Advisory Board While Advancing Invikafusp alfa Clinical Program in PD-1 Resistant Solid Tumors 

Marengo's STAR shines as Ipsen pays $45M for 2 cancer ...

Marengo has dosed the first patient in STARt-002, a Phase Ib/II trial evaluating invikafusp alfa in combination TRODELVY® (sacituzumab govitecan-hziy) HCP in metastatic breast cancer.

This milestone builds on encouraging monotherapy data in PD-1–resistant tumors and supports our strategy to advance immunotherapy-ADC combinations in broader disease settings.

We are proud to collaborate with Gilead Sciences and with leading centers including Mass General Hospital with Steven Isakofff, Sarah Cannon Research Institute with Erika Hamilton, MD, and Princess Margaret Cancer Centre with Philippe Bedard to bring new treatment options to patients.

Read Full release: https://lnkd.in/ey9jdAt6

#biotech #oncology #clinicaltrials #immunotherapy #ADC #MarengoTherapeutics #breastcancer”

Marengo Therapeutics Announces Second Drug Candidate Nomination from Strategic Collaboration with Ipsen - PR Newswire

Marengo Therapeutics is proud to announce the First-in-Human preliminary clinical results of Invikafusp alfa (STAR0602), a novel Precision dual T cell agonist, will be featured as Late-breaking Oral Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston! 

We will share our learning and insights of TCR Vβ Biology from the STARt-001 trial and our proprietary bi-specific STAR™ antibody platform which is designed to reinvigorate anti-tumor T-cell responses in PD(L)1-resistant cancers.

Join us to discuss, innovate, and work toward a future where immunotherapy transforms patient outcomes. If you have not done so already you can still Register for SITC here: https://lnkd.in/ggphnMEm
#SITC2024 #Immunotherapy #CancerResearch #Innovation #Networking

We are excited to share that, for the second consecutive year, Marengo Therapeutics has been certified as a Great Place to Work! 🏆
This recognition underscores our commitment to nurturing a positive, inclusive workplace where every team member is valued and empowered to succeed.
A heartfelt thank you to our exceptional team for their dedication, hard work, and passion. It is through their unwavering efforts that we have cultivated such a special workplace culture. 💼❤️
We are proud of this achievement and look forward to continuing to foster an environment where everyone can thrive.
#greatplacetowork #companyculture

Biotech startup Marengo unveils $80M and a new way to get T cells to fight cancer - MedCity News

Join the Marengo Therapeutics team at the IO360 Summit this week - Our CEO Zhen Su, MD MBA will be giving a plenary oral presentation. Don't miss hearing first hand how we are advancing our novel T cell agonists: Zhen's session takes place on Thursday, March 26 at 2:00pm Eastern.

Check out the full agenda: https://lnkd.in/g8ZxrHHK

#IO360Summit #marengotherapeutics #immunoonology
 

Ipsen to Pay Marengo Therapeutics Up to $1.2 Billion Under Expanded Cancer Research Partnership - WSJ

 Marengo Therapeutics Announces the Appointment of Elena Garralda, MD, PhD, to its Scientific Advisory Board 

We are thrilled to welcome Dr. Everett Vokes to our Scientific Advisory Board! Dr. Vokes is a world-renowned thoracic oncologist, former ASCO President and Chair of the Department of Medicine at the University of Chicago. His appointment follows encouraging single-agent activity of invikafusp alfa in TMB-H solid tumors such as CRC and NSCLC. We look forward to his strategic insights as we advance our first-in-class dual T cell agonists in oncology.

Read more: https://lnkd.in/e-yjpNGB

#immunotherapy #oncology #lungcancer #biotechnews #clinicaldevelopment

Today, we presented expanded monotherapy activity of invikafusp alfa at AACR 2025 Clinical Plenary in PD-1 resistant tumors. The clinical presentation demonstrated the single agent pan-tumor potential and reinforced our focused expansion into mCRC and TMB-H tumors, supported by FDA Fast Track Designation.

Read the full press release: https://lnkd.in/eRZ2KivH

Marengo wants to thank all our dedicated and caring investigators. Most importantly we would like to thank our patients and their families who are our North Star.

#oncology #immunotherapy #precisionmedicine #AACR2025 #MarengoTherapeutics #Tcellactivation #biotech #CRC #NSCLC #checkpointresistance

Earlier today Marengo CEO Zhen Su, MD MBA presented our clinical data at ESMO IO in Geneva, Switzerland. Many thanks to the trial patients and our clinical investigators. 

Read the press release here: https://lnkd.in/dJ5jXaqp

Earlier this month, our amazing team rolled up their sleeves and spent the afternoon with Community Servings, supporting their mission to provide medically tailored, nutritious, scratch-made meals to chronically and critically ill individuals and their families. It was heartwarming to see everyone come together, united by a shared purpose.
A huge thank you to Community Servings for welcoming us back to be part of this initiative for the second year in a row. We can’t wait for our next opportunity to make a positive impact!
#TeamWork #Volunteering #CommunityImpact #FoodIsMedicine

Join Marengo CEO, Zhen Su, MD MBA at the upcoming Longwood Healthcare Leaders Miami CEO event, April 9 - 11, where he will partake in a panel discussion on R&D Collaboration as part of Friday’s agenda.
 
 More information: https://lnkd.in/ebU5_dcQ
 
 #longwoodhealthcareleaders #ceo #biotech

Join our CEO, Zhen Su, MD MBA chair and present at the 6th TCR-based Therapies Summit on Wednesday, April 2. Marengo is thrilled to join alongside leading scientists and innovators in the field of TCR therapies to explore and drive the future of immunotherapy. Learn more about or register for the event here: https://lnkd.in/gF2zkg8
 
#Immunotherapy #Biotech #TCR #Innovation

 Marengo Presents Expanded Clinical Monotherapy Activity of Invikafusp Alfa in Multiple PD-1 Resistant Tumors as a Clinical Plenary Oral at AACR 2025 

Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers - Fierce Biotech

Marengo Doses First Patient in STARt-002 Clinical Trial Evaluating First-in-Class Dual T Cell Agonist, Invikafusp Alfa in Combination with TROP2-directed ADC Trodelvy® in Metastatic Breast Cancer - PR Newswire

Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire

First patient dosed as Marengo’s invikafusp alfa trial expands to Europe - Clinical Trials Arena

Marengo Announces First Patient Dosed Phase 2Clinical Study | Trending From Our Network - Chicago Star Media

 Ipsen to Pay Marengo Therapeutics Up to $1.2 Billion Under Expanded Cancer Research Partnership 

 Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen 

Experienced I-O researcher named CMO at Marengo - The Pharma Letter

 Ipsen nominates new drug candidate under Marengo oncology collaboration 

Activating T cells to fight cancer - Nature

Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy - PR Newswire

Ipsen Invests Potential $1.6B to Turbo-Charge Marengo’s Path to the Clinic - BioSpace

 Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer 

Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer - PR Newswire

Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic - Business Wire

 Multispecific molecules binding to tcr and uses thereof 

Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022 - PR Newswire

Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform - PR Newswire

Marengo Therapeutics

Business:

Drug notes:

About: